Key Points
- Insider sale: Steven Pieper sold 5,000 Xeris Biopharma shares at $8.50 each for $42,500 under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 0.37% to 1.36 million shares.
- Quarterly results: Xeris reported a quarterly loss of $0.18 per share, missing the $0.01 consensus estimate, while revenue of $92.1 million exceeded expectations of $90.12 million.
- Analyst sentiment: The stock has an average “Hold” rating and a $10.80 target price; analysts include four Buys, two Holds and one Sell, while institutional investors own 42.75% of shares.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Steven Pieper sold 5,000 shares of the firm's stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $8.50, for a total value of $42,500.00. Following the completion of the transaction, the insider owned 1,361,053 shares of the company's stock, valued at $11,568,950.50. The trade was a 0.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Steven Pieper also recently made the following trade(s):
- On Tuesday, July 7th, Steven Pieper sold 27,600 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.52, for a total value of $235,152.00.
- On Monday, July 6th, Steven Pieper sold 17,400 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.50, for a total value of $147,900.00.
Xeris Biopharma Stock Performance
XERS opened at $8.49 on Thursday. The business's 50-day simple moving average is $7.82 and its 200 day simple moving average is $6.81. Xeris Biopharma Holdings, Inc. has a 52-week low of $5.25 and a 52-week high of $10.08. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.50 and a current ratio of 2.12. The firm has a market capitalization of $1.55 billion, a PE ratio of -77.18 and a beta of 0.66.
Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of $0.01 by ($0.19). The company had revenue of $92.10 million during the quarter, compared to the consensus estimate of $90.12 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 158.10%. As a group, sell-side analysts expect that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Xeris Biopharma
Institutional investors have recently bought and sold shares of the business. Kestra Advisory Services LLC acquired a new stake in shares of Xeris Biopharma in the fourth quarter valued at approximately $25,000. KBC Group NV bought a new position in shares of Xeris Biopharma during the 1st quarter worth approximately $27,000. Allworth Financial LP acquired a new position in shares of Xeris Biopharma during the 2nd quarter worth approximately $34,000. State of Wyoming acquired a new position in shares of Xeris Biopharma during the 2nd quarter worth approximately $52,000. Finally, Caitong International Asset Management Co. Ltd raised its stake in Xeris Biopharma by 9,276.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company's stock valued at $59,000 after acquiring an additional 7,421 shares during the period. Institutional investors and hedge funds own 42.75% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities analysts recently weighed in on XERS shares. Weiss Ratings downgraded shares of Xeris Biopharma from a "hold (c-)" rating to a "sell (d-)" rating in a report on Tuesday. Wall Street Zen cut shares of Xeris Biopharma from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 8th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $10.80.
Check Out Our Latest Research Report on Xeris Biopharma
Xeris Biopharma Company Profile
(
Get Free Report)
Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company's proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.
The company's flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
